Pediatric

« Previous 12 Next »
Viewing Page 2 of 2 | Showing Results 11 - 15 of 15

Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors

This phase II trial studies how well cabozantinib-s-malate works in treating younger patients with sarcomas, Wilms tumor, or other rare tumors that...

Brenda Wittman, M.D.
  • Alaska Research
  • Providence Alaska Medical Center

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol

Objective response rate (complete response/partial response) assessed according to Response Evaluation Criteria in Solid Tumors version 1.1 [ Time...

Brenda Wittman, M.D.
  • Alaska Research
  • Providence Alaska Medical Center

Neuroblastoma Classification Biology Studies

This research trial studies biomarkers in tumor tissue samples from patients with newly diagnosed neuroblastoma or ganglioneuroblastoma. Studying...

Brenda Wittman, M.D.
  • Alaska Research
  • Providence Alaska Medical Center

A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-Lly

This phase III trial studies how well inotuzumab ozogamicin and post-induction chemotherapy work in treating patients with high-risk B-cell...

Brenda Wittman, M.D.
  • Alaska Pediatric Oncology
  • Alaska Research
  • Providence Alaska Medical Center

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia CIRB

This randomized phase III trial studies how well imatinib mesylate and combination chemotherapy work in treating patients with newly diagnosed...

Brenda Wittman, M.D.
  • Alaska Research
  • Providence Alaska Medical Center
« Previous 12 Next »
Viewing Page 2 of 2 | Showing Results 11 - 15 of 15